MetaVia Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MetaVia Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.97M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($27.59M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($12.47M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($13.97M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($15.28M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($29.68M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($21.31M) | Apr 15, 2021 |
| FY2018 | Dec 31, 2018 | ($3.66M) | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | ($6.08M) | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | ($6.68M) | Mar 18, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.71M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($28.81M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($15.89M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($19.63M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($15.30M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($29.72M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($20.18M) | Apr 15, 2021 |
| FY2018 | Dec 31, 2018 | ($3.30M) | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | ($5.91M) | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | ($6.53M) | Mar 18, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.80M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $21.55M | Mar 26, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.70M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($24.71M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($10.80M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($11.71M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($15.13M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.76M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($7.04M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($14.45M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($26.90M) | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | ($11.04M) | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $8.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $50.0K | Mar 20, 2025 |
| FY2022 | Dec 31, 2021 | $3.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $4.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $214.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $3.0K | Mar 30, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.12M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $16.26M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $22.78M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $33.53M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $16.80M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $10.97M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $14.47M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $3.82M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $19.02M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $24.75M | Mar 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.79M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $8.33M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.10M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $11.78M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.20M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.77M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.18M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $360.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $15.08M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $4.12M | Mar 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.33M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.93M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $16.69M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $21.75M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $14.60M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $7.20M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $12.29M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($13.29M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $25.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $20.63M | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($148.83M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($135.86M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($108.27M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($95.80M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($81.83M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($66.54M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($36.87M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($15.55M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($60.47M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($27.06M) | Mar 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.28M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $16.02M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $22.44M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $33.36M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $16.39M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $10.09M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $13.91M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.85M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $18.47M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $24.03M | Mar 18, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (39) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (43) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (19) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (39) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (43) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (19) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.31M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 785,194 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 4.91M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 3.18M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 888,693 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 19.67M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 15.59M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 5.17M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 10.63M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 9.27M | Mar 20, 2018 |